Perindopril

Perindopril
IUPAC ime
	(2S,3aS,7aS)-1-[(2S)-2- {[(2S)-1-etoksi-1-oksopentan-2-il]amino}propanoil]-oktahidro-1H-indol-2-karboksilna kiselina
Klinički podaci
Prodajno ime	Coversyl, Coversum, Preterax, Aceon
Drugs.com	Monografija
MedlinePlus	a602017
Kategorija trudnoće	US: D (Evidencija rizika) ; ;
Način primene	Oralno
Pravni status
Pravni status	US: ℞-only ;
Farmakokinetički podaci
Bioraspoloživost	24%
Vezivanje proteina	20%
Metabolizam	Renal
Poluvreme eliminacije	1—17 sati za perindoprilat (aktivni metabolit)
Identifikatori
CAS broj	82834-16-0
ATC kod	C09AA04 (WHO) ; C09BA04 (sa diureticima); C09BB04 (sa amlodipinom)
PubChem	CID 107807
DrugBank	DB00790
ChemSpider	96956
UNII	1964X464OJ
KEGG	D03753
ChEBI	CHEBI:8024
ChEMBL	CHEMBL1581
Hemijski podaci
Formula	C19H32N2O5
Molarna masa	368,468 g/mol
	SMILES O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@H]12)C)CCC; ;
	InChI InChI=1S/C19H32N2O5/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24/h12-16,20H,4-11H2,1-3H3,(H,23,24)/t12-,13-,14-,15-,16-/m0/s1 ; Key:IPVQLZZIHOAWMC-QXKUPLGCSA-N ;

Perindopril je dugotrajni ACE inhibitor. On se koristi za tretman visokog krvnog pritiska, zatajenja srca i koronarne arterijske bolesti^[1] u obliku perindopril arginina (Coversyl, Coversum) ili perindopril erbumina (Aceon). Ova dva preparata su terapeutski ekvivalentna.^[2]

Reference уреди

^ Royal Australian College of General Practitioners. „Consumer Medicine Information, GenRx Perindopril” (PDF). Clinical Resources, Medicine information for health professionals. Архивирано из оригинала (PDF) 01. 09. 2007. г.
^ Australian Government Department of Health and Ageing (2008). „PBS For Health Professionals”. Pharmaceutical Benefits Scheme. Архивирано из оригинала 30. 10. 2008. г. Приступљено 4. 9. 2008.

Reference уреди

Bounhoure JP, Bottineau G, Lechat P, et al.. "Value of perindopril in the treatment of chronic congestive heart failure: multicentre double-blind placebo-controlled study." Clin Exp Hypertens. 1989;A11(suppl 2):575-586.
Lechat P, Granham SP, Desche P, et al.. "Efficacy and acceptability of perindopril in mild-to-moderate chronic congestive heart failure." Am Heart J. 1993;126:798-806.
Morgan T and Anderson A; "Clinical efficacy of perindopril in hypertension." Clin Exp Pharmacol Physiol. 1992;19:61-65.
Myers MG; (on behalf of the perindopril multicentre dose-response study group) "A dose-response study of perindopril in hypertension: effects on blood pressure 6 and 24h after dosing." Can J Cardiol. 1996;12:1191-1196.
"The European trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo controlled, multicentre trial (the EUROPA study)." The Lancet 2003;362:782-788.

Spoljašnje veze уреди

Official homepage

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Royal Australian College of General Practitioners. „Consumer Medicine Information, GenRx Perindopril” (PDF). Clinical Resources, Medicine information for health professionals. Архивирано из оригинала (PDF) 01. 09. 2007. г.

[2] Australian Government Department of Health and Ageing (2008). „PBS For Health Professionals”. Pharmaceutical Benefits Scheme. Архивирано из оригинала 30. 10. 2008. г. Приступљено 4. 9. 2008.

[1]

[2]